Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Down – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares gapped down before the market opened on Monday . The stock had previously closed at $34.50, but opened at $16.77. Zenas BioPharma shares last traded at $15.61, with a volume of 2,301,078 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ZBIO shares. Morgan Stanley boosted their price objective on Zenas BioPharma from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Citigroup lifted their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a report on Monday, December 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.29.

Zenas BioPharma Stock Down 57.5%

The firm has a 50-day moving average of $36.35 and a two-hundred day moving average of $23.98. The stock has a market capitalization of $787.49 million, a price-to-earnings ratio of -2.07 and a beta of -1.45. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $2,399,985.00. Following the completion of the acquisition, the insider owned 1,917,895 shares of the company’s stock, valued at approximately $36,440,005. This trade represents a 7.05% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jason Raleigh Nunn bought 63,158 shares of the business’s stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $19.00 per share, for a total transaction of $1,200,002.00. Following the completion of the acquisition, the director owned 1,173,395 shares of the company’s stock, valued at approximately $22,294,505. This represents a 5.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 923,035 shares of company stock worth $17,628,163 in the last ninety days. Company insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Federated Hermes Inc. boosted its holdings in shares of Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after buying an additional 703,838 shares during the period. Vanguard Group Inc. lifted its position in Zenas BioPharma by 17.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after acquiring an additional 170,546 shares during the last quarter. Invesco Ltd. bought a new stake in Zenas BioPharma during the third quarter valued at about $3,237,000. Millennium Management LLC acquired a new stake in shares of Zenas BioPharma in the third quarter valued at about $1,595,000. Finally, Geode Capital Management LLC lifted its position in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.